Amedisys Inc (NASDAQ:AMED) has been assigned a consensus rating of “Hold” from the eleven analysts that are currently covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $56.00.

Several equities research analysts have recently issued reports on the stock. Royal Bank Of Canada reiterated a “hold” rating and set a $56.00 price objective on shares of Amedisys in a research report on Monday, June 5th. Mizuho cut shares of Amedisys from a “buy” rating to a “neutral” rating and set a $50.00 price objective on the stock. in a research report on Wednesday, July 26th. BidaskClub lowered shares of Amedisys from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 12th. Finally, Bank of America Corporation initiated coverage on shares of Amedisys in a report on Monday, August 21st. They issued a “neutral” rating and a $55.00 target price for the company.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/06/amedisys-inc-amed-given-average-rating-of-hold-by-brokerages.html.

Amedisys (NASDAQ:AMED) traded down 0.17% during mid-day trading on Wednesday, hitting $52.30. 34,354 shares of the stock traded hands. The stock has a market cap of $1.77 billion, a price-to-earnings ratio of 44.70 and a beta of 0.84. The company’s 50 day moving average price is $50.91 and its 200-day moving average price is $54.78. Amedisys has a 1-year low of $34.58 and a 1-year high of $65.91.

Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Wednesday, July 26th. The health services provider reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.12. The firm had revenue of $378.80 million for the quarter, compared to analysts’ expectations of $380.80 million. Amedisys had a net margin of 2.70% and a return on equity of 13.71%. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.42 earnings per share. Analysts predict that Amedisys will post $2.21 earnings per share for the current year.

In other Amedisys news, Director Bruce D. Perkins purchased 2,000 shares of the company’s stock in a transaction dated Thursday, August 3rd. The shares were acquired at an average price of $46.60 per share, for a total transaction of $93,200.00. Following the completion of the purchase, the director now owns 15,825 shares of the company’s stock, valued at $737,445. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider David B. Pearce sold 1,000 shares of the business’s stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $50.00, for a total value of $50,000.00. Following the sale, the insider now owns 10,488 shares in the company, valued at approximately $524,400. The disclosure for this sale can be found here. 2.80% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of AMED. Bank of Montreal Can boosted its position in Amedisys by 8,881.4% in the first quarter. Bank of Montreal Can now owns 34,848 shares of the health services provider’s stock valued at $1,780,000 after buying an additional 34,460 shares during the last quarter. Louisiana State Employees Retirement System boosted its position in Amedisys by 1.8% in the first quarter. Louisiana State Employees Retirement System now owns 11,400 shares of the health services provider’s stock valued at $582,000 after buying an additional 200 shares during the last quarter. State of Alaska Department of Revenue boosted its position in Amedisys by 2.3% in the first quarter. State of Alaska Department of Revenue now owns 3,080 shares of the health services provider’s stock valued at $157,000 after buying an additional 70 shares during the last quarter. Russell Investments Group Ltd. boosted its position in Amedisys by 77.7% in the first quarter. Russell Investments Group Ltd. now owns 36,295 shares of the health services provider’s stock valued at $1,854,000 after buying an additional 15,875 shares during the last quarter. Finally, Great West Life Assurance Co. Can boosted its position in Amedisys by 8.0% in the first quarter. Great West Life Assurance Co. Can now owns 40,062 shares of the health services provider’s stock valued at $2,045,000 after buying an additional 2,960 shares during the last quarter. Hedge funds and other institutional investors own 96.80% of the company’s stock.

About Amedisys

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Stock Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related stocks with our FREE daily email newsletter.